Roots Analysis has done a detailed
study on
To order this 485+ page report, which features 195+ figures
and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html
Key Market Insights
§
§ About 75 drug candidates based on synlet gene
pairs are being evaluated for the treatment of various types of cancers;
presently, there are over 20 screening platforms enabling therapy development
efforts
§ The
pipeline features both small molecules and biologic drugs based on different
synlet targets for treating a variety of oncological and non-oncological
indications
§ Innovation
in this domain is evident across the plethora of scientific articles published
in prestigious journals, highlighting key focus areas and prevalent / upcoming
trends
§ Over
time, several non-profit organizations have extended financial support to aid
research efforts in this domain; the current focus appears to be on the
identification of novel synlet targets across different clinical conditions
§ Significant
advances in research have led to the discovery of a wide array of synlet
targets; over time, substantial intellectual capital has been generated and
validated by eminent scientists from renowned research institutes
§ To
support innovation, several private and public investors have made substantial
capital investments, totalling to approximately USD 5.1 billion, across 100
instances of funding
§ The
personalized approach offered by companion diagnostics presents enormous
opportunities for drug developers to partner with diagnostic test providers to
improve patient / subject selection in clinical trials
§ Future
growth of the market is likely to be driven by the success of clinical outcomes
of late-stage molecules; industry stakeholders are optimistic about the vast
potential of PARP inhibitors
§ In the
mid to long term, the anticipated market opportunity is likely to be well
distributed across advanced cancer indications, delivery routes and various
global regions
For more information, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION TO DNA DAMAGE
AND REPAIR SYSTEMS
3.1. Chapter Overview
3.2. Overview of Deoxyribonucleic
Acid (DNA) Damage
3.3. DNA Damaging Agents
3.3.1. Endogenous DNA Damaging Agents
3.3.2. Exogenous DNA Damaging Agents
3.3.3. Other DNA Damaging Agents
3.4. DNA Damage Response System
3.4.1. Key Components of DNA Repair
System
3.5. Types of DNA Repair Systems
3.5.1. Direct Repair
3.5.1.1. Photoreactivation
3.5.1.2. Alkyl Transferase Mediated Direct
DNA Repair
3.5.1.3. AlkB Mediated Direct DNA Repair
3.5.1.4. DNA Ligase Mediated Direct DNA
Repair
3.5.2. Excision Repair
3.5.2.1. Base Excision Repair (BER)
3.5.2.1.1. BER Pathway: Key Enzymes
3.5.2.1.1.1. DNA Glycosylases
3.5.2.1.1.2. Apurinic / Apyrimidinic (AP)
Endonucleases
3.5.2.1.1.3. Other Enzymes
3.5.2.1.2. Short-Patch Base Excision Repair
3.5.2.1.3. Long-Patch Base Excision Repair
3.5.2.2. Nucleotide Excision Repair (NER)
3.5.2.3. Mismatch Repair
3.5.3. Indirect Repair
3.5.3.1. Homologous Recombination Repair
(HRR)
3.5.3.2. Non-Homologous End-Joining
3.6. Mutations in DNA Repair Genes
4. INTRODUCTION TO SYNTHETIC
LETHALITY
4.1. Chapter Overview
4.2. Concept of Synthetic
Lethality
4.2.1. Historical Evolution of
Synthetic Lethality
4.2.2. HRR and Synthetic Lethality
4.2.3. Other Synthetic Lethal Gene
Interactions
4.2.4. Advantages of Synthetic
Lethality
4.2.5. Limitations of Synthetic
Lethality
4.3. Identification of Synlet
Interactions
4.3.1. Hypothesis-Driven Approach
4.3.2. Screening-Based Approaches
4.3.2.1. Chemical Library-Based Screening
Approaches
4.3.2.1.1. Non-Annotated Libraries
4.3.2.1.2. Annotated Libraries
4.3.2.2. Genome-Wide Interference-Based
Screening Approaches
4.3.2.2.1. Ribonucleic Acid Interference (RNAi)
Based Synlet Target Identification
4.3.2.2.2. Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR) Based Synlet Target Identification
4.3.3. In Silico Approaches
4.4. Prevalent Trends Related to
Synthetic Lethality
4.4.1. Recent News on Google: Emerging
Focus Areas
4.4.2. Google Trends Analysis:
Historical Timeline
4.4.3. Google Trends Analysis:
Geographical Activity
4.4.4. Google Trends Analysis: Other
Key Terms Related to Synthetic Lethality
4.5 Concluding Remarks
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Synthetic Lethality-based
Drugs: Marketed and Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Type of Therapy
5.2.4. Analysis by Type of Synlet
Target
5.2.5. Analysis by Therapeutic Area
5.2.6. Analysis by Target Indication
5.2.7. Analysis by Patient Segment
5.2.8. Analysis by Route of
Administration
5.3. Synthetic Lethality-based
Drugs: List of Screening Platforms
5.4 Synthetic
Lethality-based Drugs: List of Drug Developers / Screening Platform Providers
5.4.1. Analysis by Year of
Establishment
5.4.2. Analysis by Location of
Headquarters
5.4.3. Analysis by Company Size
5.4.4. Analysis by Company Size and
Location of Headquarters
5.4.5. Leading Drug Developers
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Profiles of Established
Players
6.2.1. AbbVie
6.2.1.1. Company Overview
6.2.1.2. Synthetic Lethality-based Drug
Portfolio
6.2.1.2.1. Veliparib (ABT-888)
6.2.1.3. Recent Developments and Future
Outlook
6.2.2. AstraZeneca
6.2.2.1. Company Overview
6.2.2.2. Synthetic Lethality-based Drug
Portfolio
6.2.2.2.1. Olaparib (Lynparza®)
6.2.2.2.2. AZD6738
6.2.2.2.3. AZD1775
6.2.2.3. Recent Developments and Future
Outlook
6.2.3. BeiGene
6.2.3.1. Company Overview
6.2.3.2. Synthetic Lethality-based Drug
Portfolio
6.2.3.2.1. Pamiparib (BGB-290)
6.2.3.3. Recent Developments and Future
Outlook
6.2.4. Clovis Oncology
6.2.4.1. Company Overview
6.2.4.2. Synthetic Lethality-based Drug
Portfolio
6.2.4.2.1. Rucaparib (Rubraca®)
6.2.4.3. Recent Developments and Future
Outlook
6.2.5. GlaxoSmithKline
6.2.5.1. Company Overview
6.2.5.2. Synthetic Lethality-based Drug
Portfolio
6.2.5.2.1. Niraparib (Zejula®)
6.2.5.3. Recent Developments and Future
Outlook
6.2.6. Pfizer
6.2.6.1. Company Overview
6.2.6.2. Synthetic Lethality-based Drug
Portfolio
6.2.6.2.1. Talazoparib (TALZENNA®)
6.2.6.3. Recent Developments and Future
Outlook
6.3. Profiles of Small and
Mid-Sized Players
6.3.1. AtlasMedx
6.3.2. Chordia Therapeutics
6.3.3. IDEAYA Biosciences
6.3.4. Mission Therapeutics
6.3.5. Repare Therapeutics
6.3.6. Sierra Oncology
6.3.7. SyntheX Labs
7. EMERGING TRENDS ON SOCIAL
MEDIA
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Synthetic Lethality: Trends
on Twitter
7.3.1. Cumulative Year-Wise Activity
7.3.2. Historical Trends in Volume of
Tweets
7.3.3. Evolutionary Trend Analysis
7.3.4. Trending Words / Phrases on
Twitter
7.3.5. Most Prolific Contributors on
Twitter
7.3.6. Most Popular Synlet Targets /
Patient Mutations on Twitter
7.3.7. Most Popular Indications on
Twitter
7.3.8. Heat Map Analysis: Distribution
by Synlet Targets / Patient Mutations and Indications
7.4. Most Popular Tweets
7.5. Concluding Remarks
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
